Literature DB >> 1977185

Sulphasalazine and the aminosalicylates in the treatment of inflammatory bowel disease.

S A Riley1, L A Turnberg.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1977185

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


× No keyword cloud information.
  7 in total

Review 1.  Sulfasalazine. Multiplicity of action.

Authors:  T S Gaginella; R E Walsh
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

2.  Direct and metabolism-dependent toxicity of sulphasalazine and its principal metabolites towards human erythrocytes and leucocytes.

Authors:  M Pirmohamed; M D Coleman; F Hussain; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

Review 3.  Novel oral drug formulations. Their potential in modulating adverse effects.

Authors:  A T Florence; P U Jani
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

4.  What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?

Authors:  S A Riley
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

5.  Effect of olsalazine and mesalazine on human ileal and colonic (Na+ + K+)-ATPase. A possible diarrhogenic factor?

Authors:  C Scheurlen; H Allgayer; W Kruis; E Erdmann; T Sauerbruch
Journal:  Clin Investig       Date:  1993-04

6.  Tests of renal function in patients with quiescent colitis: effects of drug treatment.

Authors:  S A Riley; D R Lloyd; V Mani
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

7.  Synthesis and evaluation of mutual azo prodrug of 5-aminosalicylic acid linked to 2-phenylbenzoxazole-2-yl-5-acetic acid in ulcerative colitis.

Authors:  Jamal A Jilani; Maha Shomaf; Karem H Alzoubi
Journal:  Drug Des Devel Ther       Date:  2013-07-31       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.